News Above the Noise—Week of September 28, 2025
1. A Closer Look at Trump’s Claims on Autism, Tylenol, and Pregnancy
President Trump is facing criticism from medical experts after urging pregnant women to avoid Tylenol, claiming without evidence that the drug is linked to autism. Researchers and physicians say the claim is not supported by science and warn that discouraging necessary treatment during pregnancy could endanger both mothers and babies. As Trump repeats long-debunked theories about vaccines and autism, health leaders caution that the spread of misinformation from public figures continues to erode trust in medicine and public health guidance. Click here to learn more.
2. Many Americans Can’t Buy Homes, Get Jobs, or Move
Rising interest rates, dwindling job opportunities, and economic uncertainty are keeping many Americans from making major life moves. Home sales have dropped to lows not seen since the Great Recession, while hiring has slowed to a fraction of last year’s pace. For many Americans, opportunities for upward mobility are limited by the state of today's economy. Find out more here.
3. Firings Follow Charlie Kirk Assassination Comments
Over 145 people have been fired or disciplined over their comments about the assasination of Charlie Kirk. From nurses to professors, employers are cracking down amid public outrage and political pressure, highlighting the growing tension between free speech and workplace policies in an era of cancel culture. As the fallout spreads, experts caution this moment could reshape how companies navigate employees’ free speech and political expression. Read more.
Editor's Note: Every week, The Sunday Paper's team of journalists sift through the news to find what Rises Above the Noise, makes sense of what's happening in the world, and provides hope for your week to come. While we do our best to provide our own informative summary of each piece, some publications require their own subscriptions beyond our control.
Please note that we may receive affiliate commissions from the sales of linked products.
